Follicular Lymphoma | Topics

 
Grade I to IIA, Transformed Follicular Lymphoma Show Positive Antitumor Response to Glofitamab
March 22, 2021

In a phase 1 trial, the recommended phase 2 dose of glofitamab resulted in frequent and durable complete responses for patients with follicular lymphoma and transformed diffuse large B-cell lymphoma arising from follicular lymphoma.

FDA Approves Axi-cel in Relapsed/Refractory Follicular Lymphoma
March 06, 2021

Data from the phase 2 ZUMA-5 trial supported the approval of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with follicular lymphoma in the third-line setting.

FDA Approves Umbralisib for Patients with Previously Treated MZL & FL
February 05, 2021

The approval of umbralisib was primarily based on data from the marginal zone lymphoma and follicular lymphoma patient cohorts of the phase 2b UNITY-NHL trial.